Spondyloarthritis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

By

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Adalimumab Continuation Linked to Fewer Flares After Remission in Nonradiographic axSpA

Adalimumab Continuation Linked to Fewer Flares After Remission in Nonradiographic axSpA

By

In patients with nonradiographic axial spondyloarthritis who achieve remission with adalimumab, continued therapy was linked to fewer flares vs treatment withdrawal.

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

By

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

By

High-intensity interval training showed no clear effects on disease activity markers in patients with psoriatic arthritis.

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

By

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.

Novel Automated Mobility Measure Yields High Reproducibility in Axial Spondyloarthritis

Novel Automated Mobility Measure Yields High Reproducibility in Axial Spondyloarthritis

By

Researchers assessed the reproducibility of UCOASMI in clinical practice settings.

TNFi More Effective in Men vs Women With Psoriatic Arthritis

TNFi More Effective in Men vs Women With Psoriatic Arthritis

By

Male gender was associated with better biologic treatment effectiveness in psoriatic arthritis.

Positive Phase 3 Data Announced for Ixekizumab in Ankylosing Spondylitis

Positive Phase 3 Data Announced for Ixekizumab in Ankylosing Spondylitis

By

Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.

Gender Differences in Axial Spondyloarthritis: Comparing Disease Burden and Treatment

Gender Differences in Axial Spondyloarthritis: Comparing Disease Burden and Treatment

By

An improved understanding of the gender differences in axial spondyloarthritis can improve disease treatment and reduce disease burden.

ASAS Health Index Valid, Reliable in Axial and Peripheral Spondyloarthritis

ASAS Health Index Valid, Reliable in Axial and Peripheral Spondyloarthritis

By

The Assessment of Spondyloarthritis International Society Health Index proved to be valid, reliable, and responsive.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

By

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

By

Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.

ABT-122 Shows Similar Safety, Efficacy to Adalimumab in Psoriatic Arthritis

ABT-122 Shows Similar Safety, Efficacy to Adalimumab in Psoriatic Arthritis

By

ABT-122 demonstrated efficacy and safety similar to adalimumab over 12 weeks in patients with psoriatic arthritis who had an inadequate response to methotrexate.

FDA: Secukinumab Slows Progression of Joint Structural Damage in Psoriatic Arthritis

FDA: Secukinumab Slows Progression of Joint Structural Damage in Psoriatic Arthritis

By

The FDA has approved updated labeling for Cosentyx that includes data demonstrating that the drug slows the progression of joint structural damage in patients with active psoriatic arthritis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

By

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

By

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

By

A systematic review revealed no signal for increased pregnancy loss in patients with axial spondyloarthritis.

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

By

Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

By

Researchers sought to evaluate the efficacy, tolerability, and persistence of TNFi and ustekinumab in patients with psoriatic arthritis initiating first-line, second-line, or third-line biologic DMARDs.

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

By

Investigators assessed the 12-week efficacy and safety of bimekizumab in patients with active ankylosing spondylitis.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

By

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

By

Increased interleukin-31 levels may protect against structural damage in patients with axial spondyloarthritis.

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

By

Axial spondyloarthritis disease duration was associated with higher risk of developing acute anterior uveitis and inflammatory bowel disease, but not psoriasis.

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

By

Hidradenitis suppurativa is more common in patients with axial spondyloarthritis compared with the general population.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

By

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

By

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

By

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

By

The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.

Sign Up for Free e-newsletters